AIG
PTGX icon

American International Group’s Protagonist Therapeutics PTGX Stock Holding History

American International Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-28,149
Closed -$814K – 2068
2024
Q1 		$814K Sell
28,149
-241
-0.8% -$6.56K ﹤0.01% 1408
2023
Q4 		$651K Sell
28,390
-115
-0.4% -$2.01K ﹤0.01% 1517
2023
Q3 		$475K Buy
28,505
+2,411
+9% +$46.8K ﹤0.01% 1639
2023
Q2 		$721K Buy
26,094
+3,638
+16% +$91K ﹤0.01% 1431
2023
Q1 		$516K Buy
22,456
+447
+2% +$7.51K ﹤0.01% 1587
2022
Q4 		$240K Buy
22,009
+164
+0.8% +$1.38K ﹤0.01% 2038
2022
Q3 		$184K Buy
21,845
+308
+1% +$2.92K ﹤0.01% 2201
2022
Q2 		$170K Sell
21,537
-673
-3% -$8.14K ﹤0.01% 2297
2022
Q1 		$526K Sell
22,210
-1,562
-7% -$44K ﹤0.01% 1693
2021
Q4 		$813K Sell
23,772
-711
-3% -$22.5K ﹤0.01% 1538
2021
Q3 		$434K Buy
24,483
+1,318
+6% +$56.2K ﹤0.01% 1956
2021
Q2 		$1.04K Buy
23,165
+2,638
+13% +$87.1K ﹤0.01% 1493
2021
Q1 		$532 Buy
20,527
+2,224
+12% +$56.3K ﹤0.01% 1802
2020
Q4 		$369 Buy
18,303
+188
+1% +$4.05K ﹤0.01% 1924
2020
Q3 		$354K Buy
18,115
+4,306
+31% +$80.8K ﹤0.01% 1784
2020
Q2 		$244K Buy
13,809
+3,370
+32% +$42.3K ﹤0.01% 2011
2020
Q1 		$74K Sell
10,439
-602
-5% -$4.51K ﹤0.01% 2490
2019
Q4 		$78K Buy
11,041
+286
+3% +$2.84K ﹤0.01% 2741
2019
Q3 		$129K Buy
10,755
+1,113
+12% +$14K ﹤0.01% 2449
2019
Q2 		$117K Buy
+9,642
New +$107K ﹤0.01% 2587
2018
Q2 		– Sell
-7,285
Closed -$63K – 3108
2018
Q1 		$63K Sell
7,285
-392
-5% -$7.38K ﹤0.01% 2842
2017
Q4 		$160K Buy
7,677
+1,389
+22% +$24.6K ﹤0.01% 2455
2017
Q3 		$111K Buy
6,288
+470
+8% +$6.51K ﹤0.01% 2612
2017
Q2 		$66K Buy
5,818
+1,254
+27% +$13.4K ﹤0.01% 2921
2017
Q1 		$58K Buy
+4,564
New +$73.5K ﹤0.01% 2799

Other funds holding PTGX

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

American International Group's PTGX Position: Q2 2024 in Review

American International Group sold out of Protagonist Therapeutics (PTGX) in Q2 2024, closing a stake of 28,149 shares — an estimated $814K sold.

American International Group first reported a position in PTGX in Q1 2017 and held it in 25 quarters. The position peaked at $814K in Q1 2024. 188 funds tracked by Wall St. Rank hold PTGX as of Q2 2024.

  • American International Group reported no remaining Protagonist Therapeutics position as of Q2 2024 after selling out during the quarter.
  • American International Group sold 28,149 Protagonist Therapeutics shares in Q2 2024, an estimated $814K.
  • American International Group first reported a position in Protagonist Therapeutics in Q1 2017 and held it in 25 quarters.
  • American International Group's Protagonist Therapeutics position peaked at $814K in Q1 2024.
  • 188 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2024.

Based on American International Group's 13F filing for Q2 2024, filed 13 Aug 2024.